Cited by 250Bacterial Cancer TherapyHepatocellular Carcinoma Treatment and PrognosisAmino Acid Enzymes and Metabolism

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Pegylated Arginine Deiminase Treatment of Patients With Unresectable Hepatocellular Carcinoma: Results From Phase I/II Studies

Izzo, Francesco, Marra, Paolo, Beneduce, Gerardo, Castello, Giuseppe, Vallone, Paolo, De Rosa, Vincenzo, Cremona, Franco, Ensor, C. Mark, Holtsberg, Frederick W., Bomalaski, John S., Clark, Mike A., Ng, Chaan, Curley, Steven A.·2004·Journal of Clinical Oncology

DOI 10.1200/jco.2004.11.120

Open this paper in CoChat — free account

Abstract

Purpose: Recently, we reported that a large number of human hepatocellular cancer (HCC) cell lines were auxotrophic for arginine. Here we report the results obtained with the amino acid–degrading enzyme arginine deiminase (ADI) conjugated to polyethylene glycol (ADI-SS PEG 20,000 mw) as a means of lowering plasma arginine to treat HCC. The study was a cohort dose-escalation phase I/II study. Patients and Methods: Pharmacodynamic studies indicated an ADI-SS PEG 20,000 mw dose level of 160 U/m 2 was sufficient to lower plasma arginine from a resting level of approximately 130 μmol/L to below the level of detection (< 2 μmol/L) for more than 7 days, a dose later defined as the optimal biologic dose. All patients were to receive three cycles at the optimum biologic dose. Results: This therapy was well tolerated, even in patients who had no detectable plasma arginine for 3 continuous months of therapy. Of the 19 patients enrolled, two had a complete response, seven had a partial response, seven had stable disease, and three had progressive disease. The median survival for the 19 patients enrolled on this study was 410 days, with four patients still alive at present (> 680 days). Conclusion: Elimination of all detectable plasma arginine in patients with HCC was well tolerated and seemed to be effective in the treatment of some patients with HCC. Further testing of ADI-SS PEG 20,000 mw in a larger population of individuals with HCC as well as other human tumors auxotrophic for arginine is warranted.

Integrity signals

Registry

Crossref · 10.1200/jco.2004.11.120

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Hepatocellular Carcinoma
El‐Serag, H. B. (2002) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200211002-00002 · Cited by 633
Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults
Ryder, S. (2003) · Gut · doi:10.1136/gut.52.suppl_3.iii1 · Cited by 423
Hereditary nonpolyposis colorectal cancer (lynch syndromes I and II). I. Clinical description of resource
Lynch, H. T., Kimberling, W. J., Albano, W. A., Lynch, J. F., Biscone, K. A., Schuelke, G. S., Sandberg, A. A., Lipkin, M., Deschner, E. E., Mikol, Y. B., et al. (1985) · Cancer · doi:10.1002/1097-0142(19850815)56:4 · Cited by 400
Trends in Survival of Patients With Hepatocellular Carcinoma Between 1977 and 1996 in the United States
El‐Serag, H. B., Mason, A. C., & Key, C. R. (2001) · Hepatology · doi:10.1053/jhep.2001.21041 · Cited by 356
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers
Dillon, B. J., Prieto, V. G., Curley, S. A., Ensor, M., Holtsberg, F. W., Bomalaski, J. S., & Clark, M. A. (2004) · Cancer · doi:10.1002/cncr.20057 · Cited by 317
Self-citation
Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Ensor, M., Holtsberg, F. W., Bomalaski, J. S., & Clark, M. A. (2002) · PubMed · Cited by 315
Self-citation
Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Livers:A Clinico-Histopathologic Study of 804 North American Patients
Nzeako, U. C., Goodman, Z. D., & Ishak, K. G. (1996) · American Journal of Clinical Pathology · doi:10.1093/ajcp/105.1.65 · Cited by 230
Natural History of Untreated Primary Hepatocellular Carcinoma
Pawarode, A., Voravud, N., Sriuranpong, V., Kullavanijaya, P., & Patt, Y. Z. (1998) · American Journal of Clinical Oncology · doi:10.1097/00000421-199808000-00014 · Cited by 174
THE AMINO ACID REQUIREMENTS OF MAN
Rose, W. C., Haines, W. J., & Warner, D. T. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)50916-9 · Cited by 168

Show all 42 references

Sorted by citations

Items 101–200 of 250

NO and hepatocellular cancer
Wang, R., Geller, D. A., Wink, D. A., Cheng, B., & Billiar, T. R. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14838 · Cited by 47
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers
Chang, K., Chiang, N., Wu, S., Yen, C.-J., Chen, S., Yeh, Y., Li, C., Feng, X., Wu, K., Johnston, A. L., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1943253 · Cited by 47
Self-citation
Expression, purification, and characterization of arginine deiminase from Lactococcus lactis ssp. lactis ATCC 7962 in Escherichia coli BL21
Kim, J., Jeong, D., & Lee, H. J. (2006) · Protein Expression and Purification · doi:10.1016/j.pep.2006.12.002 · Cited by 47
The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials
Synakiewicz, A., Stachowicz‐Stencel, T., & Adamkiewicz‐Drożyńska, E. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.934808 · Cited by 45
A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies
Harding, J. J., Do, R. K., Dika, I. E., Hollywood, E. M., Uhlitskykh, K., Valentino, E., Wan, P., Hamilton, C. R., Feng, X., Johnston, A. L., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3635-3 · Cited by 44
Self-citation
Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression
Rotondo, R., Mastracci, L., Piazza, T., Barisione, G., Fabbi, M., Cassanello, M., Costa, R., Morandi, B., Astigiano, S., Cesario, A., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23437 · Cited by 45
Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma
Wu, L., Li, L., Meng, S.-C., Qi, R., Mao, Z., & Lin, M. T. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12043 · Cited by 46
Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis
Izzo, F., Montella, M., Orlando, A. P., Nasti, G., Beneduce, G., Castello, G., Cremona, F., Ensor, M., Holtzberg, F. W., Bomalaski, J. S., et al. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04463.x · Cited by 42
Self-citation
Unlocking the Potential of Arginine Deprivation Therapy: Recent Breakthroughs and Promising Future for Cancer Treatment
Chu, Y., Lai, M., & Yeh, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310668 · Cited by 44
Directed Evolution of an Antitumor Drug (Arginine Deiminase PpADI) for Increased Activity at Physiological pH
Zhu, L., Tee, K. L., Roccatano, D., Sönmez, B., Ni, Y., Sun, Z., & Schwaneberg, U. (2010) · ChemBioChem · doi:10.1002/cbic.200900717 · Cited by 41
Arginine deprivation as a new treatment strategy for head and neck cancer
Huang, C., Tsai, S., Kuo, C., Chang, J. S.-M., Jin, Y., Chang, J., & Hsiao, J. (2012) · Oral Oncology · doi:10.1016/j.oraloncology.2012.06.004 · Cited by 41
PEGylation and pharmacological characterization of a potential anti-tumor drug, an engineered arginine deiminase originated from Pseudomonas plecoglossicida
Zhang, L., Liu, M., Jamil, S., Han, R., Xu, G., & Ni, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.042 · Cited by 40
Attenuation of Argininosuccinate Lyase Inhibits Cancer Growth via Cyclin A2 and Nitric Oxide
Huang, H.-L., Hsu, H., Shieh, S.-C., Chang, Y.-S., Chen, W.-C., Cho, C.-Y., Teng, C., Su, I., Hung, W.-C., & Lai, M.-D. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0863 · Cited by 37
Decreasing the immunogenicity of arginine deiminase enzyme via structure‐based computational analysis
Zarei, M., Nezafat, N., Rahbar, M. R., Negahdaripour, M., Sabetian, S., Morowvat, M. H., & Ghasemi, Y. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1431151 · Cited by 36
Mechanisms of cell death induced by arginase and asparaginase in precursor B-cell lymphoblasts
Métayer, L. E., Brown, R. D., Carlebur, S., Burke, G. A. A., & Brown, G. C. (2018) · APOPTOSIS · doi:10.1007/s10495-018-1506-3 · Cited by 37
Argininosuccinate synthase 1, arginine deprivation therapy and cancer management
Sun, N., & Zhao, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935553 · Cited by 36
New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma
Turato, C., Balasso, A., Carloni, V., Tiribelli, C., Mastrotto, F., Mazzocca, A., & Pontisso, P. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.10.027 · Cited by 38
Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer
Hall, P. E., Ready, N., Johnston, A. L., Bomalaski, J. S., Venhaus, R. R., Sheaff, M. T., Krug, L. M., & Szlosarek, P. W. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.07.012 · Cited by 35
Self-citation
Bench-to-Bedside Studies of Arginine Deprivation in Cancer
Field, G., Pavlyk, I., & Szlosarek, P. W. (2023) · Molecules · doi:10.3390/molecules28052150 · Cited by 34
Cancer cell sensitivity to arginine deprivation in vitro is not determined by endogenous levels of arginine metabolic enzymes
Bobak, Y. P., Vynnytska‐Myronovska, B., Kurlishchuk, Y. V., Sibirny, A. А., & Stasyk, O. V. (2010) · Cell Biology International · doi:10.1042/cbi20100451 · Cited by 34
L-Canavanine potentiates the cytotoxicity of doxorubicin and cisplatin in arginine deprived human cancer cells
Nurcahyanti, A. D., & Wink, M. (2016) · PeerJ · doi:10.7717/peerj.1542 · Cited by 34
Treating advanced hepatocellular carcinoma: How to get out of first gear
Harding, J. J., & Abou‐Alfa, G. K. (2014) · Cancer · doi:10.1002/cncr.28850 · Cited by 33
Increased expression of argininosuccinate synthetase protein predicts poor prognosis in human gastric cancer
Shan, Y., Hsu, H., Lai, M.-D., Yen, M., LUO, Y.-P., & Chen, Y. (2014) · Oncology Reports · doi:10.3892/or.2014.3556 · Cited by 33
Analysis of Gene Expression Identifies Differentially Expressed Genes and Pathways Associated with Lymphatic Dissemination in Patients with Adenocarcinoma of the Esophagus
Lagarde, S. M., van Themaat, P. E. V. L., Moerland, P. D., Gilhuijs-Pederson, L. A., ten Kate, F. J. W., Reitsma, P. H., van Kampen, A. H. C., Zwinderman, A. H., Baas, F., & van Lanschot, J. J. B. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0165-y · Cited by 33
Glucose and Amino Acid Metabolic Dependencies Linked to Stemness and Metastasis in Different Aggressive Cancer Types
Chisari, A. N., Golán, I., Campisano, S., Gélabert, C., Moustakas, A., Sancho, P., & Caja, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.723798 · Cited by 33
The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma.
Savaraj, N., Wu, C., Kuo, M. T., You, M., Wangpaichitr, M., Robles, C., Spector, S. A., & Feun, L. G. (2007) · Europe PMC (PubMed Central) · Cited by 32
Expression of Arginine Deiminase from Pseudomonas plecoglossicida CGMCC2039 in Escherichia coli and Its Anti-Tumor Activity
Ni, Y., Li, Z., Sun, Z., Zheng, P., Liu, Y., Zhu, L., & Schwaneberg, U. (2009) · Current Microbiology · doi:10.1007/s00284-009-9376-0 · Cited by 32
Activation of VIPR1 suppresses hepatocellular carcinoma progression by regulating arginine and pyrimidine metabolism
Fu, Y., Liu, S., Rodrigues, R. M., Han, Y., Guo, C., Zhu, Z., He, Y., Mackowiak, B., Feng, D., Gao, B., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.71134 · Cited by 31
Rapid evolution of arginine deiminase for improved anti-tumor activity
Ni, Y., Liu, Y., Schwaneberg, U., Zhu, L., Li, N., Li, L., & Sun, Z. (2011) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-010-3051-z · Cited by 31
A novel zwitterionic copolymer with a short poly(methyl acrylic acid) block for improving both conjugation and separation efficiency of a protein without losing its bioactivity
Lin, W., Zhang, H., Wu, J., Wang, Z., Sun, H., Yuan, J., & Chen, S. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb00474k · Cited by 31
Arginine deiminase originating fromLactococcus lactisssp.lactisAmerican Type Culture Collection (ATCC) 7962 induces G1-phase cell-cycle arrest and apoptosis in SNU-1 stomach adenocarcinoma cells
Kim, J., Kim, S. C., Lee, K. W., & Lee, H. J. (2009) · British Journal Of Nutrition · doi:10.1017/s0007114509990432 · Cited by 31
Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment
Kumari, N., & Bansal, S. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04335-w · Cited by 30
Involvement of autophagy in recombinant human arginase-induced cell apoptosis and growth inhibition of malignant melanoma cells
Wang, Z., Shi, X., Li, Y., Zeng, X. L., Fan, J., Sun, Y., Xian, Z., Zhang, G., Wang, S., Hu, H., et al. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-013-5118-0 · Cited by 30
The Relationship of Arginine Deprivation, Argininosuccinate Synthetase and Cell Death in Melanoma
Savaraj, N., Wu, C., Kuo, M. T., You, M., Wangpaichitr, M., Robles, C., Spector, S. A., & Feun, L. G. (2007) · Drug Target Insights · doi:10.1177/117739280700200016 · Cited by 30
Regulated Arginine Metabolism in Immunopathogenesis of a Wide Range of Diseases: Is There a Way to Pass between Scylla and Charybdis?
Старикова, Э. А., Rubinstein, A., Mammedova, J. T., Isakov, D., & Kudryavtsev, I. V. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45040231 · Cited by 30
Isolation and identification of an arginine deiminase producing strain Pseudomonas plecoglossicida CGMCC2039
Liu, Y.-M., Sun, Z., Ni, Y., Zheng, P., Liu, Y.-P., & Meng, F. (2008) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-008-9732-4 · Cited by 28
Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy
Stone, E. M., Chantranupong, L., Gonzalez, C., O’Neal, J. F., Rani, M., Berg, C. L. V. D., & Georgiou, G. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.097 · Cited by 28
Novel molecular targets in hepatocellular carcinoma
Chow, A. K.-M., Yau, S. W.-L., & Ng, L. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i8.589 · Cited by 27
Integrity and stability of the citrulline–arginine pathway in normal and tumour cell lines
Wheatley, D. N., Kilfeather, R., Stitt, A., & Campbell, E. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.01.004 · Cited by 27
The peculiarities of cancer cell metabolism: A route to metastasization and a target for therapy
Carvalho, T. M. A., Cardoso, H. J., Figueira, M. I., Vaz, C. V., & Socorro, S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.053 · Cited by 27
Engineering an Arginine Catabolizing Bioconjugate: Biochemical and Pharmacological Characterization of PEGylated Derivatives of Arginine Deiminase from Mycoplasma arthritidis
Wang, M., Basu, A., Palm, T., Hua, J., Youngster, S. K., Hwang, L. A., Liu, H.-C., Li, X., Peng, P., Zhang, Y., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc060198y · Cited by 27
Safety, PK/PD and preliminary anti-tumor activities of pegylated recombinant human arginase 1 (BCT-100) in patients with advanced arginine auxotrophic tumors
Cheng, P., Liu, A. M., Bessudo, A., & Mussai, F. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01149-8 · Cited by 26
Reprogramming of urea cycle in cancer: Mechanism, regulation and prospective therapeutic scopes
Ghosh, N., Mahalanobish, S., & Sil, P. C. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116326 · Cited by 26
Novel systemic therapy against malignant pleural mesothelioma
Mancuso, M. R., & Neal, J. W. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.06.01 · Cited by 25
An Engineered Arginase FC Protein Inhibits Tumor GrowthIn VitroandIn Vivo
Li, L., Wang, Y., Chen, J., Cheng, B., Hu, J., Zhou, Y., Gao, X., Gao, L., Mei, X., Sun, M., et al. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/423129 · Cited by 24
Snail enhances arginine synthesis by inhibiting ubiquitination-mediated degradation of ASS1
Jia, H., Yang, Y., Li, M., Chu, Y., Song, H., Zhang, J., Zhang, D., Zhang, Q., Xu, Y., Wang, J., et al. (2021) · EMBO Reports · doi:10.15252/embr.202051780 · Cited by 23
Differential expression of argininosuccinate synthetase in serous and non‐serous ovarian carcinomas
Cheon, D., Walts, A. E., Beach, J. A., Lester, J., Bomalaski, J. S., Walsh, C., Wiedemeyer, W. R., Karlan, B. Y., & Oršulić, S. (2014) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.4 · Cited by 24
Self-citation
Kinetic characterization of arginine deiminase and carbamate kinase from Streptococcus pyogenes M49
Hering, S., Sieg, A., Kreikemeyer, B., & Fiedler, T. (2013) · Protein Expression and Purification · doi:10.1016/j.pep.2013.07.002 · Cited by 24
Pharmacologic approaches to amino acid depletion for cancer therapy
Wilder, C. S., Chen, Z., & DiGiovanni, J. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23349 · Cited by 23
Metabolomic identification of diagnostic serum-based biomarkers for advanced stage melanoma
Bayci, A., Baker, D. A., Somerset, A. E., Türkoğlu, O., Hothem, Z. A., Callahan, R. E., Mandal, R., Han, B., Bjorndahl, T. C., Wishart, D. S., et al. (2018) · Metabolomics · doi:10.1007/s11306-018-1398-9 · Cited by 25
Oxygen Sparing Effect of Bacteriotherapy in COVID-19
Ceccarelli, G., Marazzato, M., Celani, L., Lombardi, F., Piccirilli, A., Mancone, M., Trinchieri, V., Pugliese, F. R., Mastroianni, C. M., & d’Ettorre, G. (2021) · Nutrients · doi:10.3390/nu13082898 · Cited by 23
The interplay between aryl hydrocarbon receptor, H. pylori, tryptophan, and arginine in the pathogenesis of gastric cancer
Pirzadeh, M., Khalili, N., & Rezaei, N. (2020) · International Reviews of Immunology · doi:10.1080/08830185.2020.1851371 · Cited by 20
Arginine Deiminase: Current Understanding and Applications
Zarei, M., Rahbar, M. R., Morowvat, M. H., Nezafat, N., Negahdaripour, M., Berenjian, A., & Ghasemi, Y. (2018) · Recent Patents on Biotechnology · doi:10.2174/1872208313666181220121400 · Cited by 21
Abnormal arginine metabolism is associated with prognosis in patients of gastric cancer
Shi, L., Wang, Y., Jing, Y., Xu, M., Zhu, Z., & Wang, Q. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-794 · Cited by 20
Liver and Bile Duct Cancer
Abou‐Alfa, G. K., Jarnagin, W. R., Dika, I. E., D'Angelica, M. I., Lowery, M. A., Brown, K. T., Ludwig, E., Kemeny, N. E., Covey, A. M., Crane, C. H., et al. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00077-3 · Cited by 20
Exploring the Role of Metabolites in Cancer and the Associated Nerve Crosstalk
Gu, I., Gregory, E., Atwood, C., Lee, S., & Song, Y. H. (2022) · Nutrients · doi:10.3390/nu14091722 · Cited by 20
Novel Mechanistic Insights into Arginine Deiminase Pharmacology Suggest 18F-FDG Is Not Suitable to Evaluate Clinical Response in Melanoma
Stelter, L., Evans, M. J., Jungbluth, A. A., ZANZONICO, P. B., Ritter, G., Ku, T. W., Rosenfeld, E., Bomalaski, J. S., Old, L. J., & Larson, S. M. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.092973 · Cited by 18
Self-citation
Arginine starvation in colorectal carcinoma cells: Sensing, impact on translation control and cell cycle distribution
Vynnytska‐Myronovska, B., Kurlishchuk, Y. V., Chen, O., Bobak, Y. P., Dittfeld, C., Hüther, M., Kunz‐Schughart, L. A., & Stasyk, O. V. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.01.002 · Cited by 18
Three-dimensional environment renders cancer cells profoundly less susceptible to a single amino acid starvation
Vynnytska‐Myronovska, B., Kurlishchuk, Y. V., Bobak, Y. P., Dittfeld, C., Kunz‐Schughart, L. A., & Stasyk, O. V. (2013) · Amino Acids · doi:10.1007/s00726-013-1586-x · Cited by 18
Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium
de Souza, A. R., Reig, M., & Bruix, J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1225722 · Cited by 17
Arginine Is a Novel Drug Target for Arginine Decarboxylase in Human Colorectal Cancer Cells
Wei, X., Chow, H., Chong, H.-C., Leung, S.-L., Ho, M.-K., Lee, L. M.-Y., & Leung, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813741 · Cited by 18
Construction and in vitro evaluation of enzyme nanoreactors based on carboxymethyl chitosan for arginine deprivation in cancer therapy
Zeng, T., Zhang, Y., Yan, Q., Huang, Z., Zhang, L., Yi, X., Chen, J., He, G., & Yin, Y. (2017) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2017.01.023 · Cited by 17
Targeting metabolic vulnerabilities of cancer: Small molecule inhibitors in clinic
Tripathi, S. C., Fahrmann, J. F., Vykoukal, J. V., Dennison, J. B., & Hanash, S. (2018) · Cancer Reports · doi:10.1002/cnr2.1131 · Cited by 16
Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy
Carpentier, J., Pavlyk, I., Mukherjee, U., Hall, P. E., & Szlosarek, P. W. (2022) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s335117 · Cited by 16
Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20
Gupta, S., Sahu, D., Bomalaski, J. S., Frank, I., Boorjian, S. A., Thapa, P. B., Cheville, J. C., & Hansel, D. E. (2018) · Endocrine Pathology · doi:10.1007/s12022-018-9516-9 · Cited by 15
Self-citation
Prognostic Implications of Arginase and Cytokeratin 19 Expression in Hepatocellular Carcinoma After Curative Hepatectomy: Correlation With Recurrence-Free Survival
Obiorah, I. E., Chahine, J. J., Ko, K., Park, B. U., deGuzman, J., & Kallakury, B. (2019) · Gastroenterology Research · doi:10.14740/gr1156 · Cited by 15
Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma.
Stelter, L., Evans, M. J., Jungbluth, A. A., Longo, V. A., ZANZONICO, P. B., Ritter, G., Bomalaski, J. S., Old, L. J., & Larson, S. M. (2013) · PubMed · Cited by 14
Self-citation
Amino Acid Uptake Measured by [18F]AFETP Increases in Response to Arginine Starvation in ASS1-Deficient Sarcomas
Prudner, B. C., Sun, F., Kremer, J. C., Xu, J., Huang, C., Sai, K. K. S., Morgan, Z., Leeds, H., McConathy, J., & Tine, B. A. V. (2018) · Theranostics · doi:10.7150/thno.22083 · Cited by 14
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single‐arm, phase 2 study
Harding, J. J., Yang, T., Chen, Y., Feng, Y., Yen, C., Ho, C., Huang, W., Dika, I. E., Akce, M., Tan, B. R., et al. (2021) · Cancer · doi:10.1002/cncr.33870 · Cited by 14
Self-citation
Co-application of canavanine and irradiation uncouples anticancer potential of arginine deprivation from citrulline availability
Kurlishchuk, Y. V., Vynnytska‐Myronovska, B., Grosse‐Gehling, P., Bobak, Y. P., Manig, F., Chen, O., Merker, S. R., Henle, T., Löck, S., Stange, D. E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12320 · Cited by 14
Hydrophobic Mutagenesis and Semi-rational Engineering of Arginine Deiminase for Markedly Enhanced Stability and Catalytic Efficiency
Jamil, S., Liu, M., Liu, Y.-M., Han, R., Xu, G., & Ni, Y. (2015) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-015-1649-4 · Cited by 14
Arginine deprivation as a treatment approach targeting cancer cell metabolism and survival: A review of the literature
Assi, G., & Faour, W. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175830 · Cited by 13
Peptide and Protein Bioconjugation
Salmaso, S., & Caliceti, P. (2011) · Elsevier eBooks · doi:10.1016/b978-0-12-384935-9.10011-2 · Cited by 13
Evaluation of Arginine Deiminase Treatment in Melanoma Xenografts Using 18F-FLT PET
Stelter, L., Fuchs, S., Jungbluth, A. A., Ritter, G., Longo, V. A., ZANZONICO, P. B., Raschzok, N., Sauer, I. M., Bomalaski, J. S., & Larson, S. M. (2013) · Molecular Imaging and Biology · doi:10.1007/s11307-013-0655-6 · Cited by 13
Self-citation
Bioengineered arginase I increases caspase-3 expression of hepatocellular and pancreatic carcinoma cells despite induction of argininosuccinate synthetase-1
Glazer, E. S., Kaluarachchi, W. D., Massey, K. L., Zhu, C., & Curley, S. A. (2010) · Surgery · doi:10.1016/j.surg.2010.03.022 · Cited by 13
Self-citation
Amino Acid Metabolic Vulnerabilities in Acute and Chronic Myeloid Leukemias
Bhingarkar, A., Vangapandu, H. V., Rathod, S., Hoshitsuki, K., & Fernandez, C. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.694526 · Cited by 11
A modified arginine-depleting enzyme NEI-01 inhibits growth of pancreatic cancer cells
Chow, J. P. H., Cai, Y., Chow, D. T. L., Chung, S. H. K., Chau, K.-C., Ng, K.-Y., Leung, O. M., Wong, R. M. H., Law, A. W. L., Leung, Y.-O., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231633 · Cited by 12
Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma
Wu, C., You, M., Nguyen, D. M., Wangpaichitr, M., Li, Y., Feun, L. G., Kuo, M. T., & Savaraj, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147628 · Cited by 12
Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy
Walts, A. E., Bomalaski, J. S., Ines, D., & Oršulić, S. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1904-z · Cited by 12
Self-citation
Arginase Treatment Prevents the Recovery of Canine Lymphoma and Osteosarcoma Cells Resistant to the Toxic Effects of Prolonged Arginine Deprivation
Wells, J. W., Evans, C. H., Scott, M. C., Rütgen, B. C., O’Brien, T. D., Modiano, J. F., Cvetković, G., & Tepic, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054464 · Cited by 12
Arginine enzymatic deprivation and diet restriction for cancer treatment
Zam, W. (2017) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902017000300200 · Cited by 12
The Citrulline Recycling Pathway Sustains Cardiovascular Function in Arginine-Depleted Healthy Mice, but Cannot Sustain Nitric Oxide Production during Endotoxin Challenge
Yuan, Y., Mohammad, M. A., Betancourt, A., Didelija, I. C., Yallampalli, C., & Marini, J. C. (2018) · Journal of Nutrition · doi:10.1093/jn/nxy065 · Cited by 12
Reduced expression of ASS is closely related to clinicopathological features and post-resectional survival of hepatocellular carcinoma
Yang, H., Lin, M. T., Xiong, F., Yang, Y. P., Nie, X., & Zhou, R. L. (2009) · Oncology Letters · doi:10.3892/ol_00000005 · Cited by 10
Exploring the therapeutic potential of biosynthetic enzymes in cancer treatment: Innovations and implications
Afeeza, K., Dharshini, B. P., Vasugi, S., & Dilipan, E. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.139171 · Cited by 9
The emerging roles of the urea cycle in tumor microenvironment and therapies
Zhou, J., Sun, X., & Jiang, P. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.08.007 · Cited by 9
Genetics and Molecular Biology of Mesothelioma
Fennell, D. A. (2011) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-10862-4_9 · Cited by 9
RNA interference of argininosuccinate synthetase restores sensitivity to recombinant arginine deiminase (rADI) in resistant cancer cells
Wu, F. L., Liang, Y.-F., Chang, Y.-C., Yo, H.-H., Wei, M., & Shen, L. (2011) · Journal of Biomedical Science · doi:10.1186/1423-0127-18-25 · Cited by 9
Arginine Competition in Tumor Microenvironment: A Potential Target for Cancer Therapy
Zhang, J., Wang, S., Liu, H., Luo, L., & You, J. (2025) · Medicinal Research Reviews · doi:10.1002/med.70015 · Cited by 9
The exploitation of enzyme-based cancer immunotherapy
Chandan, G., Saini, A. K., Kumari, R., Chakrabarti, S., Mittal, A., Sharma, A. K., & Saini, R. V. (2022) · Human Cell · doi:10.1007/s13577-022-00821-2 · Cited by 7
Nitric oxide donor augments antineoplastic effects of arginine deprivation in human melanoma cells
Mayevska, O. M., Chen, O., Karatsai, O., Bobak, Y. P., Barska, M., Lyniv, L., Pavlyk, I., Rzhepetskyy, Y., Igumentseva, N. I., Rędowicz, M. J., et al. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.04.003 · Cited by 7
Immobilization of engineered arginase on gold-carbon nanotubes
Lee, G. K.-C., Kwok, S.-Y., Yu, C. H., Tam, K. Y., Chong, H.-C., Leung, Y., & Tsang, S. C. E. (2012) · Chemical Communications · doi:10.1039/c2cc32863a · Cited by 7
Mono-PEGylated thermostable Bacillus caldovelox arginase mutant (BCA-M-PEG20) induces apoptosis, autophagy, cell cycle arrest and growth inhibition in gastric cancer cells
Chung, S., Tam, S.-Y., Kim, C.-F., Chong, H.-C., Lee, L. M.-Y., & Leung, Y. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01265-z · Cited by 6
Systemic therapy for hepatocellular carcinoma.
Harding, J. J., & Abou‐Alfa, G. K. (2013) · PubMed · doi:10.3978/j.issn.2304-3865.2013.07.06 · Cited by 6
The addition of arginine deiminase potentiates Mithramycin A-induced cell death in patient-derived glioblastoma cells via ATF4 and cytochrome C
Linke, C., Freitag, T., Riess, C., Scheffler, J. V., del Moral, K., Schoenwaelder, N., Fiedler, T., Fiebig, A., Kaps, P., Dubinski, D., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02873-2 · Cited by 6
Cancer therapies based on enzymatic amino acid depletion
Teixeira, C. S. S., Fernandes, H. S., Fernandes, P. A., Ramos, M. J., & Cerqueira, N. M. F. S. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-46144-3.00024-6 · Cited by 6
Hepatocellular carcinoma: insights in the biological treatment beyond sorafenib.
Gafton, B., Porumb, V., Ungurianu, S., Marinca, M. V., Cocea, C., Croitoru, A. E., Balan, G. G., Miron, N., Ciuleanu, T., & Miron, L. (2014) · PubMed · Cited by 6
Exploring Metabolic Approaches for Epithelial Ovarian Cancer Therapy
Kumari, S., Gupta, S., Jamil, A., Tabatabaei, D., & Karakashev, S. V. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31495 · Cited by 5
Selective Isolation and Identification of Arginine Degrading Bacteria;the Optimized Arginine Deaminase Production by Enterobacter sp.sgn1 as a New Source of This Potentially Anti-Tumor Enzyme
Ebrahimi, N., Gharibi, S., Ghoshoon, M. B., Karimi, Z., Gholami, A., Nezafat, N., Mohkam, M., & Ghasemi, Y. (2016) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2016.60914 · Cited by 5
Guanidine-Modifying Enzymes in the Pentein Superfamily
Linsky, T. W., & Fast, W. L. (2010) · Elsevier eBooks · doi:10.1016/b978-008045382-8.00170-2 · Cited by 5
Colorectal cancer cell-derived exosomes induce metabolic reprogramming of cancer-associated fibroblasts to promote colorectal cancer growth
Pan, G., Cheng, Z., Wang, Y., Wu, C., Wang, F., Li, Q., Wang, X., Zeng, Y., Li, Y., Li, K., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-03914-0 · Cited by 4

Authors: Izzo, F., Marra, P., Beneduce, G., Castello, G., Vallone, P., De Rosa, V., Cremona, F., Ensor, C. M., Holtsberg, F. W., Bomalaski, J. S., Clark, M. A., Ng, C., & Curley, S. A.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
From the Pascale National Cancer Institute, Naples, Italy; Phoenix Pharmacologics Inc, and University of Kentucky, Lexington, KY; and M.D. Anderson Cancer Center, University of Texas, Houston, TX.
ORCID: Izzo, Francesco
Marra, Paolo
Castello, Giuseppe
Holtsberg, Frederick W.
Bomalaski, John S.
Ng, Chaan
Curley, Steven A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2004-05-15
Volume: 22
Issue: 10
Pages: 1815-1822
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2004.11.120
OpenAlex: W2168974457
Cited by: 250
References: 42
Citations by year: 2026: 5 · 2025: 6 · 2024: 7 · 2023: 11 · 2022: 9 · 2021: 14 · 2020: 10 · 2019: 7 · 2018: 16 · 2017: 16 · 2016: 15 · 2015: 13 · 2014: 14 · 2013: 15 · 2012: 15
FWCI: 7.32
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
Keywords: arginine deiminase, pegylated arginine deiminase, hepatocellular carcinoma, arginine auxotrophy, dose escalation, pharmacodynamics, tumor response, survival
MeSH terms: Adult, Aged, Drug Administration Schedule, Female, Carcinoma, Hepatocellular, Humans, Hydrolases, Injections, Intramuscular, Liver Neoplasms, Male, Middle Aged, Polyethylene Glycols, Tomography, X-Ray Computed, Cohort Studies, Survival Analysis, Treatment Outcome, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pegylated Arginine Deiminase Treatment of Patients With Unresectable Hepatocellular Carcinoma: Results From Phase I/II Studies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks